Literature DB >> 32959759

Case Report: Confirmation by Metagenomic Sequencing of Visceral Leishmaniasis in an Immunosuppressed Returned Traveler.

Eloise Williams1,2, Nicole S Isles3, Torsten Seemann3, Trevor Kilpatrick4,5,6, Andrew Grigg7, Marcel Leroi2,1, Benjamin P Howden3,1, Jason C Kwong3,1.   

Abstract

There has been increased interest in using metagenomic next-generation sequencing as an unbiased approach for diagnosing infectious diseases. We describe a 61-year-old man on fingolimod therapy for multiple sclerosis with an extensive travel history who presented with 7 months of fevers, night sweats, and weight loss. Peripheral blood tests showed pancytopenia and abnormal acute phase reactants. A bone marrow aspirate showed the presence of numerous intracellular and extracellular amastigotes consistent with visceral leishmaniasis (VL). Metagenomic sequencing of the bone marrow aspirate confirmed Leishmania infantum, a species widely reported in the Mediterranean region. This correlated with acquisition of VL infection during the patient's most recent epidemiological exposure in southern Italy 12 months prior. This case demonstrates the potential application of metagenomic sequencing for identification and speciation of Leishmania in cases of VL; however, further assessment is required using other more readily obtained clinical samples such as blood.

Entities:  

Mesh:

Year:  2020        PMID: 32959759      PMCID: PMC7646797          DOI: 10.4269/ajtmh.19-0841

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  13 in total

Review 1.  Leishmania infections: Molecular targets and diagnosis.

Authors:  Mohammad Akhoundi; Tim Downing; Jan Votýpka; Katrin Kuhls; Julius Lukeš; Arnaud Cannet; Christophe Ravel; Pierre Marty; Pascal Delaunay; Mohamed Kasbari; Bruno Granouillac; Luigi Gradoni; Denis Sereno
Journal:  Mol Aspects Med       Date:  2017-01-31

2.  Visceral leishmaniasis infection in a fingolimod-treated multiple sclerosis patient.

Authors:  A K Artemiadis; G Nikolaou; D Kolokythopoulos; N Tegos; A Terentiou; N Triantafyllou; I Papanastasiou
Journal:  Mult Scler       Date:  2014-11-28       Impact factor: 6.312

Review 3.  Multiple sclerosis treatment with fingolimod: profile of non-cardiologic adverse events.

Authors:  Yara Dadalti Fragoso
Journal:  Acta Neurol Belg       Date:  2017-05-20       Impact factor: 2.396

4.  Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management.

Authors:  Ann M Arvin; Jerry S Wolinsky; Ludwig Kappos; Michele I Morris; Anthony T Reder; Carlo Tornatore; Anne Gershon; Michael Gershon; Myron J Levin; Mauritz Bezuidenhoudt; Norman Putzki
Journal:  JAMA Neurol       Date:  2015-01       Impact factor: 18.302

5.  FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis.

Authors:  M Mehling; V Brinkmann; J Antel; A Bar-Or; N Goebels; C Vedrine; C Kristofic; J Kuhle; R L P Lindberg; L Kappos
Journal:  Neurology       Date:  2008-10-14       Impact factor: 9.910

Review 6.  The relationship between leishmaniasis and AIDS: the second 10 years.

Authors:  Jorge Alvar; Pilar Aparicio; Abraham Aseffa; Margriet Den Boer; Carmen Cañavate; Jean-Pierre Dedet; Luigi Gradoni; Rachel Ter Horst; Rogelio López-Vélez; Javier Moreno
Journal:  Clin Microbiol Rev       Date:  2008-04       Impact factor: 26.132

7.  Visceral leishmaniasis and immunocompromise as a risk factor for the development of visceral leishmaniasis: a changing pattern at the hospital for tropical diseases, london.

Authors:  Kate Fletcher; Rita Issa; D N J Lockwood
Journal:  PLoS One       Date:  2015-04-01       Impact factor: 3.240

8.  Diagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH).

Authors:  Naomi Aronson; Barbara L Herwaldt; Michael Libman; Richard Pearson; Rogelio Lopez-Velez; Peter Weina; Edgar Carvalho; Moshe Ephros; Selma Jeronimo; Alan Magill
Journal:  Am J Trop Med Hyg       Date:  2016-12-07       Impact factor: 2.345

9.  Sphingosine-1-phosphate signaling in Leishmania donovani infection in macrophages.

Authors:  Mohd Arish; Atahar Husein; Rahat Ali; Shams Tabrez; Farha Naz; Mohammad Zulfazal Ahmad; Abdur Rub
Journal:  PLoS Negl Trop Dis       Date:  2018-08-17

10.  Fingolimod modulates peripheral effector and regulatory T cells in MS patients.

Authors:  Laura D Serpero; Gilberto Filaci; Alessia Parodi; Florinda Battaglia; Francesca Kalli; Davide Brogi; Giovanni Luigi Mancardi; Antonio Uccelli; Daniela Fenoglio
Journal:  J Neuroimmune Pharmacol       Date:  2013-05-07       Impact factor: 4.147

View more
  4 in total

1.  Case Report: Leishmaniasis in a 33-Year-Old Man with Multiple Sclerosis.

Authors:  Alvaro Guerra-Amor; Ane Lopez-Gonzalez; Pau Bosch-Nicolau; Breogan Rodriguez-Acevedo; Ana Zabalza; Elena Sulleiro; Juan Espinosa-Pereiro; Maria Luisa Aznar; Fernando Salvador; Adrián Sánchez-Montalvá; Israel Molina
Journal:  Am J Trop Med Hyg       Date:  2022-07-05       Impact factor: 3.707

Review 2.  Precision Medicine in Control of Visceral Leishmaniasis Caused by L. donovani.

Authors:  Eduard E Zijlstra
Journal:  Front Cell Infect Microbiol       Date:  2021-11-09       Impact factor: 5.293

Review 3.  Non-Endemic Leishmaniases Reported Globally in Humans between 2000 and 2021-A Comprehensive Review.

Authors:  Rafael Rocha; André Pereira; Carla Maia
Journal:  Pathogens       Date:  2022-08-16

4.  The Potential Role of Clinical Metagenomics in Infectious Diseases: Therapeutic Perspectives.

Authors:  Camille d'Humières; Maud Salmona; Sarah Dellière; Stefano Leo; Christophe Rodriguez; Cécile Angebault; Alexandre Alanio; Slim Fourati; Vladimir Lazarevic; Paul-Louis Woerther; Jacques Schrenzel; Etienne Ruppé
Journal:  Drugs       Date:  2021-07-30       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.